Menstrual-cycle restoration (return of spontaneous menses or low FSH confirming ovarian activity) is reported in 30–50% of treated women. Pregnancy achievement (either spontaneously or via assisted fertility) occurs in 15–35% of treated women across published trials, though baseline fertility potential, age, and concomitant treatments substantially influence outcomes.
Thirty-five completed trials and 3 actively recruiting trials are registered for POI cell therapy, predominantly using autologous or allogeneic placental MSCs and fetal-derived cell preparations. Trial designs vary from direct ovarian injection to systemic intravenous infusion. Outcomes tracked include restored menstruation, improved hormone levels (oestradiol, FSH), pregnancy achievement, and ultrasound evidence of follicle development. Approximately 30–50% of treated women report return of menstrual cycles within 3–6 months; pregnancy rates (per cycle or per treatment) vary widely (10–40% in published small series) and are confounded by concurrent fertility treatments (in-vitro fertilisation, egg freezing).
Sono un candidato? → · Premature Ovarian Insufficiency: full overview → · Costo Insufficienza Ovarica Prematura → · Cost →
Rivisto medicalmente dal team editoriale di StemCellAtlas con Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) della clinica partner Stem Plus (Sofia), rispetto alle linee guida ISSCR, FDA e EMA. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita